Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Still a Buy?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares gapped up prior to trading on Friday . The stock had previously closed at $16.59, but opened at $17.2450. Daiichi Sankyo shares last traded at $17.27, with a volume of 1,553 shares traded.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold”.

Daiichi Sankyo Price Performance

The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $32.38 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 3.02 and a beta of -0.17. The stock’s 50-day moving average is $16.38 and its two-hundred day moving average is $18.05.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.18). The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, equities analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.96 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.